Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
A:Long-acting interferon alpha-2a (135ug) + ribavirin
B:Abidol + ribavirin
Sponsors
Foshan First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 65 years old; (2) Patients with mild or normal type who have been diagnosed with new type of coronavirus infection [in accordance with the diagnostic criteria of the Notice on Printing and Distributing New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Implementation) issued by the National Health and Medical Commission]; (3) According to the National Health and Health Commission's antiviral treatment for more than 10 days, the COVID-19 nucleic acid examination of the throat swabs/putum /stool samples was still positive or weakly positive.
Exclusion criteria
Exclusion criteria: (1) Female patients who are pregnant or planning to become pregnant within 7 months; (2) ALT is higher than 10 times the upper limit of normal value, or total bilirubin is highter than 2 times the upper limit of normal value, or the stage of decompensation of cirrhosis, or has had decompensation of cirrhosis; (3) The number of peripheral blood leukocytes and/or platelets is lower than the lower limit of normal value; (4) There are serious important organs such as cardiovascular,lung,kidney,brain lesions and fundus lesions; (5) Combined with autoimmune disease,mental illness,diabetes,and abnormal thyroid function (hyperthyroidism or hypothyroidism); (6) Those diagnosed or suspected of malignant tumors; (7) Those who are using immunosuppressive drugs or after organ transplantation or who are preparing to undergo organ transplantation; (8) Drug addicts or people with HIV infection; (9) Those who are allergic to interferon; (10) There are other situations in which interferon is not suitable for use by the doctor in charge; (11) Men who did not take effective contraception during and after the treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Causal mortality;COVID-19 nucleic acid negative conversion rate;All-cause mortality; | — |
Countries
China
Contacts
Public ContactBin Zhang/Yinong Ye
Department of Infectious Diseases, Foshan First People's Hospital
Outcome results
None listed